


1. Participant Flow



2. Baseline Characteristics

	KRG group (n=30)	Placebo group (n=31)
Gender (M/F)	17/13	19/12
Age (years)	59.3 ± 8.79	59.7 ± 7.22
BMI (kg/m ²)	24.7 ± 2.93	24.8 ± 2.82
DM duration (years)	11.6 ± 6.80	12.6 ± 8.83
DM medication		
Mono therapy	9 (30.0%)	11 (35.5%)
Dual therapy	13 (43.3%)	8 (25.8%)
Triple therapy	18 (26.7%)	12 (38.7%)
SBP (mmHg)	131.6 ± 15.64	132.2 ± 16.77
DBP (mmHg)	77.7 ± 8.71	80.8 ± 12.03
Smoking		
Non-smoker	16 (53.3%)	20 (64.5%)
Ex-smoker	3 (10.0%)	5 (16.1%)
Current smoker	11 (36.7%)	6 (19.4%)
Alcohol		
No	22 (73.3%)	22 (71.0%)
Yes	8 (26.7%)	9 (29.0%)

3. Outcome Measures

(1) Primary outcome

	KRG group (n=30)		Placebo group (n=31)	
	Week 0	Week 24	Week 0	Week 24
CPT				
Right Lex				
2000Hz	302.55±83	266.83±80	295.54±87	256.79±80
250Hz	134.52±40	113.21±36	140.68±55	118.93±35
5Hz	88.07±38	77.90±27	93.11±33	82.79±33
Left LEx				
2000Hz	297.55±82	270.28±82	288.86±93	266.86±72
250Hz	128.76±40	106.62±36	137.29±67	107.39±35
5Hz	85.28±24	69.83±23	91.71±35	70.96±27
eGFR				
(MDRD)	89.6 ± 11.33	89.5 ± 13.07	96.4 ± 7.92	96.8 ± 6.83
Urine ACr				
(mg/gCr)	39.4 ± 148.29	27.1 ± 96.53	40.5 ± 84.07	45.0 ± 92.58
KIM-1				
(pg/mL)	118.75 ± 92.79	105.92 ± 133.52	233.01 ± 448.35	172.04 ± 309.38
Laminin-P1				
(mcg/mL)	2.09 ± 1.00	1.81 ± 0.55	1.94 ± 0.60	1.71 ± 0.46

(2) Secondary outcome

	KRG group (n=30)		Placebo group (n=31)	
	Week 0	Week 24	Week 0	Week 24
HbA1c (%)	7.4 ± 0.79	7.5 ± 0.83	7.4 ± 0.70	7.7 ± 0.85
FPG (mg/dL)	143 ± 30.41	150 ± 31.98	153 ± 30.09	159 ± 39.33

4. Adverse Events

	KRG group	Placebo group
AE	1.Dyspepsia	1.Fatigue 2.Reflux esophagitis
SAE	1.Admission due to worsen HbA1c (8.6 → 10.7 %) 2.Admission due to foot pain	